Testing immunogenicity of recombinant antibody by surface plasmon resonance.
- Author:
Liang CHANG
1
;
Xiao-Zhi LIU
;
Wei ZHAO
;
Yan-Ling LIU
;
Xiang-Feng DONG
;
Xue-Jing CHEN
;
Li-Min LI
;
Yan JIANG
;
Jian GAO
;
Jing-Shuang WEI
Author Information
1. New Drug Research and Development Company Limited, North China Pharmaceutical Corporation, Shijiazhuang 050015, China.
- Publication Type:Journal Article
- MeSH:
Antibodies, Anti-Idiotypic;
analysis;
blood;
immunology;
Antibodies, Monoclonal;
analysis;
blood;
immunology;
Antibodies, Viral;
analysis;
blood;
immunology;
Humans;
Rabies virus;
immunology;
Recombinant Proteins;
analysis;
blood;
immunology;
Surface Plasmon Resonance
- From:
Acta Pharmaceutica Sinica
2013;48(4):532-535
- CountryChina
- Language:Chinese
-
Abstract:
With the development of bio-technological drugs, drug immunogenicity evaluation has become key factor of clarifying safety and efficacy of these drugs. It has become the focus to establish a stable and reliable evaluation system. Due to the advantages such as continuous real-time monitoring, surface plasmon resonance (SPR) technology has been widely used in bio-technological drugs immunogenicity assessments. Our study applied this technology to detect anti-drug antibody (ADA) of a recombinant human anti-rabies monoclonal antibody NM57 in the sera of 48 volunteers admitted in phase I clinical trials. This method could satisfy the basic requirements of detection of ADA.
